ArticleJournal of the American Heart Association2015
Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4-Year Follow-Up.
Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04515095 (A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis.Medicine · 2020Pooled it
- The Burden, Outcomes, and Management of Patients with Aldosterone Dysregulation: A Targeted Literature Review.Advances in therapy · 2026Review
- Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation.American journal of hypertension · 2026Article
- Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.World journal of cardiology · 2025Review
- Salivary free aldosterone awakening response and cardiovascular risk in men with CHD, hypertension, and healthy controls.Frontiers in endocrinology · 2025Article
- Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk.Frontiers in endocrinology · 2024Article
- Increased daytime and awakening salivary free aldosterone in essential hypertensive men.Frontiers in cardiovascular medicine · 2024Article
- Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study.Frontiers in endocrinology · 2024Article
- Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence.Heart failure reviews · 2023Review
- MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data.Frontiers in endocrinology · 2022Article
- Risk Factors Associated With Lower Bone Mineral Density in Primary Aldosteronism Patients.Frontiers in endocrinology · 2022Article
- The mineralocorticoid receptor-an emerging player in metabolic syndrome?Journal of human hypertension · 2021Review
- Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.The Journal of clinical endocrinology and metabolism · 2020Observational
- Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.Mayo Clinic proceedings · 2018Article
- Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study.Journal of the Endocrine Society · 2017Article
- Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Frontiers in endocrinology · 2017Review
- PGC-1α overexpression protects against aldosterone-induced podocyte depletion: role of mitochondria.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundWe recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2). METHODS AND
resultsWe measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits.
conclusionsAldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.